This content is machine translated Metastatic colorectal cancer Comparison between bevacizumab and cetuximab in KRAS exon2 wild type. According to preliminary results of a large phase III trial presented at this year’s ASCO congress, bevacizumab and cetuximab (combined with FOLFOX or FOLFIRI) show similar efficacy in terms of…
View Post 3 min This content is machine translated 2nd EORTC St. Gallen Gastrointestinal Cancer Conference 2014 VEGF inhibition in metastatic colorectal cancer. The use of the VEGF inhibitor bevacizumab improves the outcome of patients with metastatic colorectal cancer regardless of the chemotherapy chosen. Recent data suggest that the duration of VEGF inhibition…
View Post 6 min This content is machine translated Interview at ASCO GI on new data from the OPUS study. “We are a good step closer to personalized therapy in mCRC” In the treatment of metastatic colorectal cancer, there were new results on subgroup analyses of the OPUS trial at this year’s ASCO GI in San Francisco. As previously shown in…
